BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

...2019.The price for a year’s supply of Gleevec...
...the committee that “over the years since Gleevec...
...did not explain how the value of Gleevec...
BioCentury | Oct 1, 2020
Politics, Policy & Law

House committee targets Mallinckrodt, Amgen and Novartis over price increases

...approved in 1998 and 2002, respectively; and Gleevec...
...in the yearly price Novartis charges for Gleevec...
...from physicians the brand name version of Gleevec...
BioCentury | Aug 13, 2020
Emerging Company Profile

RA-incubated Aerovate to deploy $72.6M series A for inhaled imatinib for PAH

...flow; however, they don’t address the core issue of proliferation. When Novartis AG (NYSE:NVS; SIX:NOVN) took cancer drug Gleevec imatinib through...
...University PartnersPresident: Benjamin Dake Patents: None issued Danielle Golovin imatinib (AV-101) Gleevac, Gleevec, Glivec, imatinib mesylate (QTI571, CGP 57148B, Ruvise, STI-571) Aerovate...
BioCentury | May 13, 2020
Product Development

Gilead secures global access to remdesivir via generic manufacturing deals

...to test repurposed and novel agents in the clinic. Exvastat Ltd. in Ireland will test Gleevec...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...has a very different list of options than he or she had 20 years ago. Gleevec...
...Gleevec, most CML patients died within five to seven years. Today, CML patients who receive Gleevec...
...few years and remain in remission; for them, Gleevec and second-generation therapies are a cure. Gleevec...
BioCentury | Nov 18, 2019

Tyrosine kinase inhibitors for the treatment of pemphigus

...Science Technology and Research, Singapore email: kaba@kuhp.kyoto-u.ac.jp Claire Quang Gleevac, Gleevec, Glivec, imatinib mesylate (QTI571, CGP 57148B, Ruvise, STI-571) Agency...
BioCentury | Aug 29, 2019
Emerging Company Profile

Hesperos: uniting organs on a chip

...a Hesperos and Roche team used a bone marrow cancer and liver system to show Gleevec...
BioCentury | Aug 13, 2019
Clinical News

Big gain for Deciphera as GIST readout portends face-off with Blueprint

...vs. 6.6 months; HR=0.36; nominal p=0.0004). INVICTUS tested ripretinib in patients who had previously received Gleevec...
...in a larger indication, second-line GIST, in the Phase III INTRIGUE trial following treatment with Gleevec...
BioCentury | Jun 5, 2019
Company News

BMS brings in Novartis exec to round out post Celgene acquisition team

...oncology development at Novartis where he helped build out the pharma's cancer pipeline past blockbuster Gleevac...
BioCentury | May 15, 2019
Distillery Therapeutics

Inhibiting PIM2 sensitizes CML to Gleevec

...culture and mouse studies suggest inhibiting PIM2 could sensitize CML to the dual BCR-ABL/c-Kit inhibitor Gleevec...
...HSCs and two Gleevec-resistant human CML cell lines, the pan-PIM kinase inhibitor tool compound plus Gleevec...
...Massachusetts Medical School, Worcester, Mass. email: Michael.Green@umassmed.edu Claire Quang Gleevac, Gleevec, Glivec, imatinib mesylate (QTI571, CGP 57148B, Ruvise, STI-571) PIM447...
Items per page:
1 - 10 of 780